MCID: CND002
MIFTS: 54

Conduct Disorder malady

Categories: Mental diseases

Aliases & Classifications for Conduct Disorder

Summaries for Conduct Disorder

Disease Ontology : 12 A specific developmental disorder marked by a pattern of repetitive behavior wherein the rights of others or social norms are violated.

MalaCards based summary : Conduct Disorder is related to personality disorder and autism spectrum disorder. An important gene associated with Conduct Disorder is MAOA (Monoamine Oxidase A), and among its related pathways/superpathways are Peptide ligand-binding receptors and Transmission across Chemical Synapses. The drugs Dopamine and Methylphenidate have been mentioned in the context of this disorder. Affiliated tissues include brain, testes and cortex, and related phenotypes are behavior/neurological and cardiovascular system

Wikipedia : 71 Conduct disorder (CD) is a mental disorder diagnosed in childhood or adolescence that presents itself... more...

Related Diseases for Conduct Disorder

Diseases related to Conduct Disorder via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 116)
id Related Disease Score Top Affiliating Genes
1 personality disorder 29.4 ALDH2 COMT DRD2 DRD4 MAOA POMC
2 autism spectrum disorder 29.1 COMT DRD4 DRD5 POMC SLC6A3 SLC6A4
3 schizophrenia 28.4 ADORA2A COMT DRD2 DRD4 DRD5 GRIN1
4 impulse control disorder 11.4
5 oppositional defiant disorder 11.2
6 cardiomyopathy, dilated, 1e 10.9
7 familial progressive cardiac conduction defect 10.8
8 wolff-parkinson-white syndrome 10.8
9 heart conduction disease 10.8
10 cardiac conduction defect 10.8
11 heart block, progressive, type ia 10.8
12 attention deficit-hyperactivity disorder 10.4
13 nephronophthisis 13 10.2 COMT SLC6A4
14 intracranial cavernous angioma 10.2 DRD2 SLC6A3 SLC6A4
15 splenic abscess 10.2 DRD2 SLC6A3 SLC6A4
16 18p deletion syndrome 10.2 DRD2 DRD4 SLC6A3
17 c8 deficiency, type ii 10.2 COMT DRD2 DRD4
18 cholestasis-lymphedema syndrome 10.2 COMT MAOA
19 tinea pedis 10.2 MAOA SLC6A3 SLC6A4
20 ornithosis 10.2 DRD2 MAOA SLC6A4
21 intrahepatic gall duct cancer 10.2 COMT MAOA SLC6A4
22 nephrogenic adenoma of the urethra 10.2 DRD2 SLC6A3 SLC6A4
23 chronic eosinophilic pneumonia 10.2 COMT MAOA SLC6A4
24 rhinoscleroma 10.1 COMT DRD2
25 conjunctival pigmentation 10.1 MAOA SLC6A4
26 alzheimer disease 17 10.1 DRD4 SLC6A4 TPH1
27 hypoglycemic coma 10.1 MAOA SLC6A4 TPH1
28 apperceptive agnosia 10.1 COMT DRD2 OXTR SLC6A4
29 antisocial personality disorder 10.1
30 renpenning syndrome 10.1 COMT MAOA SLC6A4 TPH1
31 multiple personality disorder 10.0 COMT MAOA SLC6A4 TPH1
32 sphenoorbital meningioma 10.0 DRD2 DRD4
33 alopecia 10.0 ALDH2 DRD2 DRD4 SLC6A4
34 postencephalitic parkinson disease 10.0 DRD2 MAOA SLC6A4 TPH1
35 pyromania 10.0 DRD2 DRD4 MAOA SLC6A3 SLC6A4
36 rectosigmoid junction neoplasm 10.0 DRD2 DRD4 DRD5 SLC6A3
37 cytomegalic congenital adrenal hypoplasia 10.0 COMT DRD2 DRD4 MAOA SLC6A4
38 parotid gland cancer 10.0 COMT DRD2 SLC6A3 TPH1
39 alcohol dependence 10.0
40 substance abuse 10.0
41 extraosseous chondrosarcoma 9.9 POMC SLC6A4
42 brain glioblastoma multiforme 9.9 COMT DRD2 SLC6A3 SLC6A4 TPH1
43 bipolar disorder 9.9
44 colorectal adenocarcinoma 9.9 COMT DRD2 DRD4 MAOA SLC6A3 SLC6A4
45 aortic valve disease 2 9.9 COMT DRD2 DRD4 DRD5 SLC6A3
46 hypoglycemia 9.9 DRD2 POMC SLC6A4
47 hemolytic anemia, cd59-mediated, with or without immune-mediated polyneuropathy 9.9 COMT POMC SLC6A4
48 microcephaly 13, primary, autosomal recessive 9.9 DRD2 DRD4 DRD5 MAOA SLC6A4
49 chronic conjunctivitis 9.9 COMT DRD2 DRD4 SLC6A3 SLC6A4 TPH1
50 transmitted_by 9.9 DRD2 POMC SLC6A3 SLC6A4

Comorbidity relations with Conduct Disorder via Phenotypic Disease Network (PDN):


Acute Cystitis Alzheimer Disease
Deficiency Anemia Schizophreniform Disorder

Graphical network of the top 20 diseases related to Conduct Disorder:



Diseases related to Conduct Disorder

Symptoms & Phenotypes for Conduct Disorder

MGI Mouse Phenotypes related to Conduct Disorder:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.28 MAOA OXTR POMC SLC6A3 SLC6A4 TPH1
2 cardiovascular system MP:0005385 10.1 MAOA POMC SLC6A4 TPH1 ADAM10 ADORA2A
3 homeostasis/metabolism MP:0005376 10.07 POMC SLC6A3 SLC6A4 TPH1 ADAM10 ADORA2A
4 endocrine/exocrine gland MP:0005379 10.02 DRD5 OXTR POMC SLC6A3 SLC6A4 ADAM10
5 growth/size/body region MP:0005378 10.02 ADAM10 ADORA2A ALDH2 DRD2 GRIN1 OXTR
6 integument MP:0010771 9.81 ADORA2A ALDH2 CAMK2A DRD2 OXTR POMC
7 nervous system MP:0003631 9.8 ADAM10 ADORA2A ALDH2 CAMK2A COMT DRD2
8 normal MP:0002873 9.17 ADAM10 DRD2 DRD5 GRIN1 OXTR SLC6A3

Drugs & Therapeutics for Conduct Disorder

Drugs for Conduct Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 740)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 51-61-6, 62-31-7 681
2
Methylphenidate Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 113-45-1 4158
3
Risperidone Approved, Investigational Phase 4,Phase 3,Phase 2 106266-06-2 5073
4
Dextroamphetamine Approved, Illicit Phase 4,Phase 2,Phase 1 51-64-9 5826
5
Valproic Acid Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 99-66-1 3121
6
Carbidopa Approved Phase 4,Phase 2,Phase 3 28860-95-9 34359 38101
7
Levodopa Approved Phase 4,Phase 2,Phase 3 59-92-7 6047
8
Topiramate Approved Phase 4,Phase 3,Phase 2,Phase 1 97240-79-4 5284627
9
Guanfacine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 29110-47-2 3519
10
Citalopram Approved Phase 4,Phase 3,Phase 2,Phase 1 59729-33-8 2771
11
Fluoxetine Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 54910-89-3 3386
12
Fluvoxamine Approved, Investigational Phase 4,Phase 3 54739-18-3 3404 5324346
13
Paroxetine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 61869-08-7 43815
14
Sertraline Approved Phase 4,Phase 3,Phase 2,Phase 1 79617-96-2 68617
15
Memantine Approved, Investigational Phase 4,Phase 2,Phase 3,Early Phase 1 19982-08-2 4054
16
Alprazolam Approved, Illicit, Investigational Phase 4,Phase 2,Phase 3 28981-97-7 2118
17
Aripiprazole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 129722-12-9 60795
18
Clonidine Approved Phase 4,Phase 2 4205-90-7 2803
19
Nicotine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 54-11-5 942 89594
20
Ethanol Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 64-17-5 702
21
Lamotrigine Approved, Investigational Phase 4,Phase 2,Phase 1 84057-84-1 3878
22
Acamprosate Approved, Investigational Phase 4,Phase 3 77337-76-9 71158
23
Orlistat Approved, Investigational Phase 4,Phase 2 96829-58-2 3034010
24
Bupropion Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 34841-39-9, 34911-55-2 444
25
Eszopiclone Approved Phase 4,Phase 1 138729-47-2 969472
26
Benzocaine Approved Phase 4,Phase 2,Phase 3,Phase 1 1994-09-7, 94-09-7 2337
27
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
28
Rocuronium Approved Phase 4 119302-91-9, 143558-00-3 441290
29
Aspirin Approved, Vet_approved Phase 4,Phase 2 50-78-2 2244
30
Cilostazol Approved Phase 4 73963-72-1 2754
31
Everolimus Approved Phase 4 159351-69-6 6442177
32
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3 22916-47-8 4189
33
Sirolimus Approved, Investigational Phase 4 53123-88-9 5284616 6436030 46835353
34
Ticlopidine Approved Phase 4 55142-85-3 5472
35
Amphetamine Approved, Illicit Phase 4,Phase 2,Phase 3,Phase 1 300-62-9 5826 3007
36
Naltrexone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 16590-41-3 5360515
37
Cycloserine Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 68-41-7 401 6234
38
Cocaine Approved, Illicit Phase 4,Phase 3,Phase 2,Phase 1 50-36-2 5760 446220
39
Varenicline Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 249296-44-4 5310966
40
Mifepristone Approved, Investigational Phase 4,Phase 2 84371-65-3 55245
41
Oxytocin Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 50-56-6 439302 53477758
42
Propranolol Approved, Investigational Phase 4,Phase 2,Phase 1 525-66-6 4946
43
Norepinephrine Approved Phase 4,Phase 3,Phase 2,Phase 1 51-41-2 439260
44
Mirtazapine Approved Phase 4,Phase 3,Phase 2,Phase 1 85650-52-8, 61337-67-5 4205
45
Menthol Approved Phase 4,Phase 3,Phase 2 2216-51-5 16666
46
Acetylcysteine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 616-91-1 12035
47
Trazodone Approved, Investigational Phase 4,Phase 3,Phase 1 19794-93-5 5533
48
Amitriptyline Approved Phase 4,Phase 3 50-48-6 2160
49
Heroin Approved, Illicit Phase 4,Phase 3,Phase 1 561-27-3 5462328
50
Methadone Approved Phase 4,Phase 3,Phase 2,Phase 1 76-99-3 4095

Interventional clinical trials:

(show top 50) (show all 5000)
id Name Status NCT ID Phase
1 Methylphenidate vs. Risperidone for the Treatment of Children and Adolescents With ADHD and Disruptive Disorders Unknown status NCT02063945 Phase 4
2 Effectiveness of Combined Medication Treatment for Aggression in Children With Attention Deficit With Hyperactivity Disorder (The SPICY Study) Unknown status NCT00794625 Phase 4
3 Remission of ICD by Switching Dopamine Agonist to Levodopa/Carbidopa Unknown status NCT01683253 Phase 4
4 Methylphenidate in ADHD With Trichotillomania Unknown status NCT00552266 Phase 4
5 Topiramate in the Treatment of Pathological Gambling Unknown status NCT00245583 Phase 4
6 Intuniv vs Placebo in the Treatment of Childhood Intermittent Explosive Disorder Unknown status NCT02048241 Phase 4
7 Magnetic Resonance Imaging Study of Cognitive-Behavior Therapy for Major Depressive Disorder Unknown status NCT01460212 Phase 4
8 Comparing Treatments for Self-Injury and Suicidal Behavior in People With Borderline Personality Disorder Unknown status NCT00834834 Phase 4
9 Cost-Effectiveness of Adding Web-Based Cognitive-Behavioral Therapy (CBT) to Luvox CR for Obsessive Compulsive Disorder (OCD) Unknown status NCT00743834 Phase 4
10 Study of Memantine to Treat Huntington's Disease Unknown status NCT00652457 Phase 4
11 Drug Treatment Validation of Functional Magnetic Resonance Imaging in Generalized Anxiety Disorder Unknown status NCT00662259 Phase 4
12 Role of Dopamine on Loss Aversion Behaviour: Study on Parkinsonian Patients Unknown status NCT01780467 Phase 4
13 Study to Evaluate the Efficacy and Safety of Aripiprazole Unknown status NCT02069977 Phase 4
14 Study of Clonidine on Sleep Architecture in Children With Tourette's Syndrome (TS) and Comorbid ADHD Unknown status NCT00152750 Phase 4
15 Treatment of Mild and Subthreshold Depressive Disorders Unknown status NCT00226642 Phase 4
16 Nicotine Treatment of Impulsivity in Parkinson's Disease Unknown status NCT01216904 Phase 4
17 Event-related Potentials in Management of Children With Attention-deficit/Hyperactivity Disorder Unknown status NCT01130467 Phase 4
18 Effects of an Exercise Program in Patients With Hypertensive Chronic Kidney Disease Unknown status NCT01155128 Phase 4
19 Associated Genes With Atomoxetine Response in Attention Deficit Hyperactivity Disorder (ADHD) Unknown status NCT01339286 Phase 4
20 American Migraine Prevention Study Unknown status NCT00363506 Phase 4
21 Attention Deficit Disorder Medication Response Study Unknown status NCT01727414 Phase 4
22 Treatment of Alcohol Dependence and Comorbid Bipolar Disorder Unknown status NCT01015586 Phase 4
23 Acamprosate vs. Placebo in Bipolar Alcoholics Unknown status NCT00466661 Phase 4
24 Iloperidone in Mixed States of Bipolar Disorder Unknown status NCT02413918 Phase 4
25 A Comprehensive Intervention for Diabetes and Comorbid Depression in Primary Care Unknown status NCT00939250 Phase 4
26 Increasing Cure Rate of Hepatitis C Therapy in Obese Hepatitis C Patients Unknown status NCT00871845 Phase 4
27 Efficacy of Omega-3 Fatty Acids on Borderline Personality Disorder Unknown status NCT00437099 Phase 4
28 Fluoxetine and Bupropion to Treat Patients With Depression and Alcoholism Unknown status NCT00449007 Phase 4
29 Improving Outcomes in Psychosis Associated With Substance Use Using Aripiprazole Unknown status NCT01155544 Phase 4
30 Dental Caries Management by Risk Assessment: Identification and Treatment of Risk Factors Among (IDF) Personnel Unknown status NCT01142440 Phase 4
31 Brain Mechanisms and Targeting Insomnia in Major Depression Unknown status NCT00628914 Phase 4
32 Lisdexamfetamine's Effect In ADHD in the Brain and Cognition Unknown status NCT02170298 Phase 4
33 Effects of Ramelteon (8mg) Alone and in Combination With Multi-Component Behavioral Therapy on Sleep and Circadian Phase in Patients With Chronic Insomnia Unknown status NCT01180855 Phase 4
34 Improving Sleep and Psychological Functioning in People With Depression and Insomnia Unknown status NCT00247624 Phase 4
35 Deep vs Moderate Neuromuscular Blockade With Rocuronium in Patients Undergoing Endolaryngeal Procedures Unknown status NCT02451202 Phase 4
36 Controlled Trial of Deep Brain Stimulation in Early Patients With Parkinson's Disease Unknown status NCT00354133 Phase 4
37 Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis - SAfety & EffectiveneSS of Drug-ElUting Stents & Anti-platelet REgimen Unknown status NCT01267734 Phase 4
38 The Efficacy and Safety of Oral Oxcarbazepine 300-1200 mg/Day as Adjuvant Therapy in the Treatment of Adolescents With Impulsivity and Aggressive Behavior in Conduct Disorder This Study is Not Being Conducted in the United States. Completed NCT00154362 Phase 4
39 Trial of Aripiprazole in the Treatment of CD in Adolescents Completed NCT00250705 Phase 4
40 Early Prevention of Conduct Problems Completed NCT00051714 Phase 4
41 Medication Strategies for Treating Aggressive Behavior in Youth With Attention Deficit Hyperactivity Disorder Completed NCT00228046 Phase 4
42 Depakote (Divalproex Sodium) for Children With Temper Dysregulation and Severe Mood Swings Completed NCT02078596 Phase 4
43 Metabolic Effects of Antipsychotics in Children Completed NCT00205699 Phase 4
44 Escitalopram for the Treatment of Self-Injurious Skin Picking Completed NCT00115011 Phase 4
45 Sertraline and Habit Reversal in the Treatment of Patients With Trichotillomania Completed NCT00118014 Phase 4
46 Acamprosate in the Treatment of Pathological Gambling Completed NCT00571103 Phase 4
47 Olanzapine in the Treatment of Hair Pulling (Trichotillomania) Completed NCT00182507 Phase 4
48 Treatment of Pathological Gambling With Naltrexone Pharmacotherapy and Brief Intervention Completed NCT01528007 Phase 4
49 Naltrexone for Impulse Control Disorders in Parkinson's Disease Completed NCT01052831 Phase 4
50 Comparison of Atomoxetine Versus Placebo in Children and Adolescents With ADHD and Comorbid ODD in Germany Completed NCT00406354 Phase 4

Search NIH Clinical Center for Conduct Disorder

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cochrane evidence based reviews: conduct disorder

Genetic Tests for Conduct Disorder

Anatomical Context for Conduct Disorder

MalaCards organs/tissues related to Conduct Disorder:

39
Brain, Testes, Cortex, Amygdala, Thyroid, Fetal Brain, Temporal Lobe

Publications for Conduct Disorder

Articles related to Conduct Disorder:

(show top 50) (show all 628)
id Title Authors Year
1
A Systematic Review and Meta-analysis of Neuroimaging in Oppositional Defiant Disorder (ODD) and Conduct Disorder (CD) Taking Attention-Deficit Hyperactivity Disorder (ADHD) Into Account. ( 26846227 )
2016
2
Ventral striatum and amygdala activity as convergence sites for early adversity and conduct disorder. ( 27694318 )
2016
3
Mediating and Moderating Role of Depression, Conduct Disorder or Attention-Deficit/Hyperactivity Disorder in Developing Adolescent Substance Use Disorders: A Population-Based Study. ( 27294778 )
2016
4
Does comorbid anxiety counteract emotion recognition deficits in conduct disorder? ( 26934047 )
2016
5
Callous unemotional traits, autism spectrum disorder symptoms and empathy in boys with oppositional defiant disorder or conduct disorder. ( 27575651 )
2016
6
Gene x environment interactions in conduct disorder: Implications for future treatments. ( 27545756 )
2016
7
The clinical usefulness of the new LPE specifier for subtyping adolescents with conduct disorder in the DSM 5. ( 26725044 )
2016
8
The role of anxiety in cortisol stress response and cortisol recovery in boys with oppositional defiant disorder/conduct disorder. ( 27521740 )
2016
9
Practitioner Review: Psychological treatments for children and adolescents with conduct disorder problems - a systematic review and meta-analysis. ( 27501434 )
2016
10
Linkage between pain sensitivity and empathic response in adolescents with autism spectrum conditions and conduct disorder symptoms. ( 27305862 )
2016
11
Fairness decisions in response to emotions: a functional MRI study among criminal justice-involved boys with conduct disorder. ( 26926604 )
2016
12
Commentary: Conduct disorder and perceiving harm to others - a reflection on Michalska etA al. (2016). ( 26968315 )
2016
13
Acute effects of methylphenidate on impulsivity and attentional behavior among adolescents comorbid for ADHD and conduct disorder. ( 27816696 )
2016
14
Different brain responses during empathy in autism spectrum disorders versus conduct disorder and callous-unemotional traits. ( 26681358 )
2016
15
Mapping the structural organization of the brain in conduct disorder: replication of findings in two independent samples. ( 27306512 )
2016
16
Investigating the Familial Basis of Heightened Risk-Taking in Adolescents With Conduct Disorder and Their Unaffected Relatives. ( 27031280 )
2016
17
Annual Research Review: Transdiagnostic neuroscience of child and adolescent mental disorders - differentiating decision making in attention-deficit/hyperactivity disorder, conduct disorder, depression, and anxiety. ( 26705858 )
2016
18
Abnormal serotonin transporter availability in the brains of adults with conduct disorder. ( 27771175 )
2016
19
Prospective Investigation of Video Game Use in Children and Subsequent Conduct Disorder and Depression Using Data from the Avon Longitudinal Study of Parents and Children. ( 26820149 )
2016
20
Default mode network activity and neuropsychological profile in male children and adolescents with attention deficit hyperactivity disorder and conduct disorder. ( 27738997 )
2016
21
Disrupted Topological Patterns of Large-Scale Network in Conduct Disorder. ( 27841320 )
2016
22
Understanding heterogeneity in conduct disorder: A review of psychophysiological studies. ( 27693700 )
2016
23
Genetic influences on conduct disorder. ( 27350097 )
2016
24
Exploring the clinical utility of the DSM-5 conduct disorder specifier of 'with limited prosocial emotions' in an adolescent inpatient sample. ( 27423352 )
2016
25
Childhood adversity and conduct disorder: A developmental pathway to violence in schizophrenia. ( 26879586 )
2016
26
Do neurocognitive deficits in decision making differentiate conduct disorder subtypes? ( 26832949 )
2016
27
Correlates of conduct disorder among inmates of a Nigerian Borstal Institution. ( 27330558 )
2016
28
Emotion Regulation Difficulties in Boys with Oppositional Defiant Disorder/Conduct Disorder and the Relation with Comorbid Autism Traits and Attention Deficit Traits. ( 27420110 )
2016
29
Impaired executive function in 14- to 16-year-old boys with conduct disorder is related to recidivism: A prospective longitudinal study. ( 26864806 )
2016
30
Commentary: Transdiagnostic neuroscience of child and adolescent mental disorders - differentiating decision-making in attention-deficit/hyperactivity disorder, conduct disorder, depression and anxiety. A commentary on Sonuga-Barke etA al. (2016). ( 26889895 )
2016
31
Exploring possible association between DI^H genotype (C1021T), early onset of conduct disorder and psychopathic traits in juvenile delinquents. ( 26616837 )
2016
32
Long-Term Outcomes of Attention-Deficit/Hyperactivity Disorder and Conduct Disorder: AA Systematic Review and Meta-Analysis. ( 27663939 )
2016
33
Further Evidence for Smoking and Substance Use Disorders in Youth With Bipolar Disorder and Comorbid Conduct Disorder. ( 27574842 )
2016
34
Predicting Risky Sexual Behavior: the Unique and Interactive Roles of Childhood Conduct Disorder Symptoms and Callous-Unemotional Traits. ( 27812906 )
2016
35
Association of trauma, Posttraumatic Stress Disorder and Conduct Disorder: a systematic review and meta-analysis. ( 28017839 )
2016
36
Reduced Default Mode Connectivity in Adolescents With Conduct Disorder. ( 27566121 )
2016
37
Stability Subtypes of Callous-Unemotional Traits and Conduct Disorder Symptoms and Their Correlates. ( 27299762 )
2016
38
Empathic Accuracy in Male Adolescents with Conduct Disorder and Higher versus Lower Levels of Callous-Unemotional Traits. ( 28032270 )
2016
39
Exploring the relationship difficulties of Iranian adolescents with conduct disorder: a qualitative content analysis. ( 26812767 )
2016
40
Pharmacotherapy of conduct disorder: Challenges, options and future directions. ( 27436231 )
2016
41
Regional grey matter volume and concentration in at-risk adolescents: Untangling associations with callous-unemotional traits and conduct disorder symptoms. ( 27479922 )
2016
42
Cortisol levels at baseline and under stress in adolescent males with attention-deficit hyperactivity disorder, with or without comorbid conduct disorder. ( 27280522 )
2016
43
Conduct disorder in females is associated with reduced corpus callosum structural integrity independent of comorbid disorders and exposure to maltreatment. ( 26784968 )
2016
44
A boy with conduct disorder (CD), attention deficit hyperactivity disorder (ADHD), borderline intellectual disability, and 47,XXY syndrome in combination with a 7q11.23 duplication, 11p15.5 deletion, and 20q13.33 deletion. ( 27651829 )
2016
45
Risk of Suicide Attempt among Adolescents with Conduct Disorder: A Longitudinal Follow-up Study. ( 27453371 )
2016
46
Which Kindergarten Children Are at Greatest Risk for Attention-Deficit/Hyperactivity and Conduct Disorder Symptomatology as Adolescents? ( 26192391 )
2015
47
Beyond Symptom Counts for Diagnosing Oppositional Defiant Disorder and Conduct Disorder? ( 25788042 )
2015
48
The Pharmacological Management of Oppositional Behaviour, Conduct Problems, and Aggression in Children and Adolescents With Attention-Deficit Hyperactivity Disorder, Oppositional Defiant Disorder, and Conduct Disorder: A Systematic Review and Meta-Analysis. Part 1: Psychostimulants, Alpha-2 Agonists, and Atomoxetine. ( 25886655 )
2015
49
The Associations Between Pre- and Postnatal Maternal Symptoms of Distress and Preschooler's Symptoms of ADHD, Oppositional Defiant Disorder, Conduct Disorder, and Anxiety. ( 26647350 )
2015
50
Brain response to viewing others being harmed in children with conduct disorder symptoms. ( 26472591 )
2015

Variations for Conduct Disorder

Expression for Conduct Disorder

Search GEO for disease gene expression data for Conduct Disorder.

Pathways for Conduct Disorder

Pathways related to Conduct Disorder according to GeneCards Suite gene sharing:

(show all 22)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.41 ADORA2A DRD2 DRD4 DRD5 GRIN1 OXTR
2
Show member pathways
12.86 ALDH2 CAMK2A COMT GRIN1 MAOA SLC6A3
3 12.43 CAMK2A COMT GRIN1 POMC TPH1
4
Show member pathways
12.23 CAMK2A COMT DRD2 DRD4 DRD5 GRIN1
5 12.2 DRD2 DRD4 DRD5 GRIN1
7
Show member pathways
12.07 ADORA2A CAMK2A DRD5 GRIN1 OXTR
8 12.05 GRIN1 MAOA SLC6A4 TPH1
9
Show member pathways
12 CAMK2A DRD2 DRD4 DRD5 GRIN1
10 11.94 ADORA2A DRD5 POMC
11
Show member pathways
11.94 ADORA2A CAMK2A DRD2 DRD5 GRIN1 OXTR
12
Show member pathways
11.82 DRD2 DRD4 DRD5
13 11.81 MAOA SLC6A4 TPH1
14
Show member pathways
11.72 CAMK2A DRD2 GRIN1 MAOA SLC6A3
15
Show member pathways
11.26 ADORA2A MAOA SLC6A3 SLC6A4
16 11.13 MAOA SLC6A4 TPH1
17
Show member pathways
11.01 COMT MAOA TPH1
18 11 DRD2 DRD5
19
Show member pathways
10.76 ALDH2 COMT MAOA
20 10.71 COMT MAOA
21
Show member pathways
10.67 ALDH2 MAOA
22
Show member pathways
10.45 ALDH2 COMT MAOA SLC6A3 SLC6A4

GO Terms for Conduct Disorder

Cellular components related to Conduct Disorder according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 dendrite GO:0030425 9.71 ADORA2A COMT DRD2 GRIN1
2 axon GO:0030424 9.62 ADORA2A COMT DRD2 SLC6A3
3 integral component of plasma membrane GO:0005887 9.56 ADORA2A DRD2 DRD4 DRD5 GRIN1 OXTR
4 neuron projection GO:0043005 9.55 CAMK2A GRIN1 SLC6A3 SLC6A4 TPH1
5 dendritic spine GO:0043197 9.54 COMT DRD2 GRIN1
6 non-motile cilium GO:0097730 9.46 DRD2 DRD5
7 postsynaptic density GO:0014069 9.02 ADAM10 ADORA2A CAMK2A DRD2 GRIN1
8 integral component of membrane GO:0016021 10.17 ADAM10 ADORA2A COMT DRD2 DRD4 DRD5
9 plasma membrane GO:0005886 10 ADAM10 ADORA2A CAMK2A COMT DRD2 DRD4

Biological processes related to Conduct Disorder according to GeneCards Suite gene sharing:

(show all 47)
id Name GO ID Score Top Affiliating Genes
1 response to organic cyclic compound GO:0014070 9.87 COMT OXTR SLC6A3
2 response to ethanol GO:0045471 9.85 DRD2 GRIN1 SLC6A3
3 response to drug GO:0042493 9.85 ADORA2A COMT DRD2 OXTR SLC6A3 SLC6A4
4 cellular calcium ion homeostasis GO:0006874 9.83 DRD4 DRD5 GRIN1
5 locomotory behavior GO:0007626 9.8 ADORA2A DRD2 SLC6A3
6 memory GO:0007613 9.74 GRIN1 OXTR SLC6A4
7 learning GO:0007612 9.72 COMT DRD5 GRIN1
8 arachidonic acid secretion GO:0050482 9.7 DRD2 DRD4
9 behavioral response to cocaine GO:0048148 9.7 DRD2 DRD4
10 regulation of neuronal synaptic plasticity GO:0048168 9.69 CAMK2A GRIN1
11 positive regulation of synaptic transmission, glutamatergic GO:0051968 9.69 ADORA2A OXTR
12 dopamine receptor signaling pathway GO:0007212 9.69 DRD2 DRD4
13 synaptic transmission, glutamatergic GO:0035249 9.68 ADORA2A GRIN1
14 response to iron ion GO:0010039 9.68 DRD2 SLC6A3
15 regulation of long-term neuronal synaptic plasticity GO:0048169 9.68 DRD2 GRIN1
16 startle response GO:0001964 9.67 DRD2 GRIN1
17 behavioral response to ethanol GO:0048149 9.67 DRD2 DRD4
18 neurotransmitter biosynthetic process GO:0042136 9.67 SLC6A3 SLC6A4
19 ammonium transmembrane transport GO:0072488 9.66 SLC6A3 SLC6A4
20 positive regulation of urine volume GO:0035810 9.65 ADORA2A DRD2
21 positive regulation of renal sodium excretion GO:0035815 9.65 ADORA2A DRD2
22 negative regulation of protein secretion GO:0050709 9.65 DRD2 DRD4
23 positive regulation of synaptic transmission, GABAergic GO:0032230 9.64 ADORA2A OXTR
24 suckling behavior GO:0001967 9.64 GRIN1 OXTR
25 phospholipase C-activating dopamine receptor signaling pathway GO:0060158 9.63 DRD2 DRD5
26 negative regulation of voltage-gated calcium channel activity GO:1901386 9.63 DRD2 DRD4
27 associative learning GO:0008306 9.63 DRD2 DRD5 GRIN1
28 neurotransmitter catabolic process GO:0042135 9.62 COMT MAOA
29 social behavior GO:0035176 9.62 DRD4 GRIN1 OXTR SLC6A4
30 adenylate cyclase-inhibiting dopamine receptor signaling pathway GO:0007195 9.61 DRD2 DRD4
31 catecholamine metabolic process GO:0006584 9.61 COMT MAOA
32 synaptic transmission, dopaminergic GO:0001963 9.61 ADORA2A DRD2 DRD5
33 regulation of dopamine metabolic process GO:0042053 9.6 DRD4 SLC6A3
34 adenohypophysis development GO:0021984 9.59 DRD2 SLC6A3
35 positive regulation of adenylate cyclase activity involved in G-protein coupled receptor signaling pathway GO:0010579 9.58 ADORA2A DRD5
36 monoamine transport GO:0015844 9.58 SLC6A3 SLC6A4
37 dopamine metabolic process GO:0042417 9.58 COMT DRD2 DRD4
38 inhibitory postsynaptic potential GO:0060080 9.56 ADORA2A DRD4
39 sperm ejaculation GO:0042713 9.54 OXTR SLC6A4
40 dopamine uptake involved in synaptic transmission GO:0051583 9.52 SLC6A3 SLC6A4
41 regulation of systemic arterial blood pressure by vasopressin GO:0001992 9.51 DRD5 OXTR
42 positive regulation of dopamine uptake involved in synaptic transmission GO:0051586 9.49 DRD2 DRD4
43 response to histamine GO:0034776 9.48 DRD2 DRD4
44 response to cocaine GO:0042220 9.46 DRD2 DRD5 OXTR SLC6A3
45 dopamine catabolic process GO:0042420 9.43 COMT MAOA SLC6A3
46 prepulse inhibition GO:0060134 9.26 ADORA2A DRD2 GRIN1 SLC6A3
47 response to amphetamine GO:0001975 9.1 ADORA2A DRD2 DRD4 DRD5 GRIN1 OXTR

Molecular functions related to Conduct Disorder according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 G-protein coupled receptor activity GO:0004930 9.88 ADORA2A DRD2 DRD4 DRD5 OXTR
2 signal transducer activity GO:0004871 9.72 ADORA2A DRD2 DRD4 DRD5 OXTR
3 receptor binding GO:0005102 9.65 ADAM10 DRD2 GRIN1 POMC SLC6A3
4 drug binding GO:0008144 9.61 DRD2 DRD4 SLC6A3
5 neurotransmitter:sodium symporter activity GO:0005328 9.46 SLC6A3 SLC6A4
6 dopamine neurotransmitter receptor activity, coupled via Gi/Go GO:0001591 9.4 DRD2 DRD4
7 monoamine transmembrane transporter activity GO:0008504 9.37 SLC6A3 SLC6A4
8 dopamine:sodium symporter activity GO:0005330 9.16 SLC6A3 SLC6A4
9 dopamine neurotransmitter receptor activity GO:0004952 9.13 DRD2 DRD4 DRD5
10 dopamine binding GO:0035240 8.92 DRD2 DRD4 DRD5 SLC6A3

Sources for Conduct Disorder

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....